EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSPEMG00000021620
Gene Symbol: GART
3 Cross references
215 Possible Orthologues:

Plasminogen

Ensembl ID : ENSPEMG00000006099
Gene Symbol: PLG
3 Cross references
239 Possible Orthologues:

Plasminogen Activator, Tissue

Ensembl ID : ENSPEMG00000011572
Gene Symbol: PLAT
1 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSPEMG00000025544
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSPEMG00000007844
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSPEMG00000016131
Gene Symbol: PDGFRB
1 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSPEMG00000010524
Gene Symbol: PDGFB
3 Cross references
261 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSPEMG00000018738
Gene Symbol: PLK4
1 Cross references
208 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 1

Ensembl ID : ENSPEMG00000020230
Gene Symbol: PARP1
1 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSPEMG00000000567
Gene Symbol: PARP3
1 Cross references
199 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSPEMG00000000490
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSPEMG00000018381
Gene Symbol: PORCN
3 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).